z-logo
open-access-imgOpen Access
Variations in Opioid Responsiveness
Author(s) -
Howard S. Smith
Publication year - 2008
Publication title -
pain physician
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 99
eISSN - 2150-1149
pISSN - 1533-3159
DOI - 10.36076/ppj.2008/11/237
Subject(s) - medicine , postherpetic neuralgia , opioid , analgesic , pharmacogenetics , morphine sulfate , intensive care medicine , chronic pain , pharmacodynamics , bioinformatics , pharmacology , morphine , neuropathic pain , psychiatry , pharmacokinetics , receptor , biochemistry , chemistry , biology , genotype , gene
It has been appreciated for some time now that humans react differently to opioids. Aspecific opioid such as morphine sulfate may have specific analgesic effects for certainpatients with postherpetic neuralgia whereas in other patients with postherpetic neuralgia, it may provide quite different analgesic qualities. Also, in any one individual patienta particular opioid may provide better analgesia than other opioids. Furthermore, thesedifferences are not unique to analgesia; they can also be seen with other opioid effects/toxicities. Though many of the differences can be classified neatly into pharmacokinetic and pharmacodynamic differences, there are certain differences which still remain incompletely understood. Also, clinicians are not yet able to easily predict which patientswill respond well or poorly to various opioids. As research unravels the various genetics,biochemical, and receptor interaction differences of opioids in humans, it is hoped thateasily obtainable, cost-effective testing will become available to aid clinicians in choosing an optimal opioid analgesic for an individual patient, a process which is currently accomplished via health care provider judgment along with trial and error. In the future,knowledge gained from databases on knockout rodents, pharmacogenetics, and genepolymorphisms may impact on the ability of clinicians to predict patient responses todoses of specific opioids in efforts to individualize optimal opioid analgesic therapy. It isconceivable that eventually information of this type may translate into improved patientcare. In the future, armed with data of this type, clinicians may become quite adept attailoring appropriate opioid therapy as well as optimal opioid rotation strategies.Key words: Opioids, pain, analgesic responsiveness, OPRM1 118G, muopioid receptor, gene polymorphism

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here